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The tRNA synthetases catalyze the first step of protein synthesis and have increasingly been studied for their nuclear and extra-cellular
ex-translational activities. Human genetic conditions such as Charcot-Marie-Tooth have been attributed to dominant gain-of-function
mutations in some tRNA synthetases. Unlike dominantly inherited gain-of-functionmutations, recessive loss-of-functionmutations can
potentially elucidate ex-translational activities. We present here five individuals from four families with a multi-system disease associ-
ated with bi-allelic mutations in FARSB that encodes the beta chain of the alpha2beta2 phenylalanine-tRNA synthetase (FARS). Collec-
tively, the mutant alleles encompass a 50-splice junction non-coding variant (SJV) and six missense variants, one of which is shared by
unrelated individuals. The clinical condition is characterized by interstitial lung disease, cerebral aneurysms and brain calcifications, and
cirrhosis. For the SJV, we confirmed exon skipping leading to a frameshift associated with noncatalytic activity. While the bi-allelic com-
bination of the SJV with a p.Arg305Gln missense mutation in two individuals led to severe disease, cells from neither the asymptomatic
heterozygous carriers nor the compound heterozygous affected individual had any defect in protein synthesis. These results support a
disease mechanism independent of tRNA synthetase activities in protein translation and suggest that this FARS activity is essential for
normal function in multiple organs.Introduction
The universal aminoacyl tRNA synthetase (aaRS) family
of enzymes is necessary for protein synthesis and is
increasingly implicated in key signaling pathways outside
of protein synthesis. In that connection, they have been
associated with previously unrecognized human diseases
and functions.1–5 aaRSs have nuclear and extra-cellular
activities that in some cases integrate translation with
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functions correlates with the addition of novel domains,
such as nuclear localization signals or receptor-binding
motifs, which are not essential for aminoacylation.6–13
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Mutations in cytoplasmic and mitochondrial aaRSs
in humans are associated with neuropathies, leukoence-
phalopathies, myopathies, hepatopathies, and lung
disorders.15–18 Dominant missense mutations in aaRSs
associated with Charcot-Marie-Tooth disease (CMTD)
are the most common, and in some cases have been stud-
ied in mechanistic detail.19 More than a dozen different
CMTD mutations have been described in glycyl-tRNA
synthetase (GARS).20 For some mutations, an extracel-
lular form of mutant GARS binds neuropilin-1 to block
binding of vascular endothelial growth factor A to its re-
ceptor and interferes with a critical neuronal signaling
pathway.21,22 While these dominant gain-of-function
mutations are informative, recessive aminoacylation-
disruptive mutations in aaRSs might be most useful for
elucidating a novel function of aaRSs beyond protein
translation.
The phenotypes associated with recessive mutations
emerge because cytoplasmic and mitochondrial genes for
aaRSs are single copy and, with rare exception, there are
distinct genes for the cytoplasmic and mitochondrial
forms. Bi-allelic mutations in genes for lysyl, glycyl, me-
thionyl-, isoleucyl-, glutamyl-, and arginyl-tRNA synthe-
tases have been reported.23–30 Phenotypes associated
with these mutations are variable and whether they arise
from defects in protein synthesis has either not been
explored or is controversial. However, mice haploinsuffi-
cient for GARS have a 50% decrease in enzymatic activity
in vitro and in tissues, but nonetheless have a normal
phenotype and lifespan.31 Thus, if protein synthesis is
not dramatically affected, humans with one loss-of-func-
tion allele or retaining some residual activity might be
viable.
Here, we report five individuals from four independent
families with bi-allelic mutations in the gene for the beta
chain of FARS (MIM: 609690) associated with a complex,
unique phenotype associated with cholesterol pneumo-
nitis, cerebral aneurysms and calcifications, and liver
cirrhosis. The associated phenotype can be lethal and is
more severe than that observed with most other recessive
aaRS diseases reported to date. In our study, we investi-
gated one family in detail and demonstrate no impact of
these mutations on protein synthesis in cells. These data
are thus consistent with the bi-allelic mutations causing
a change in one or more FARSB functions outside of pro-
tein synthesis. These functions appear to be essential for
multiple organ function.Material and Methods
Informed consent was obtained from all participants included in
the study. The Institutional Review Board of Columbia University,
the National Research Ethics Service Committee North East – New-
castle & North Tyneside 1, and the Ethics Committee of the Uni-
versity of Munich, Germany32 approved this study. All of the
procedures followedwere in accordance with the ethical standards
of each institution.The AmDNA Extraction and Exome Sequencing
Genomic DNA was extracted from whole blood from proband 1,
his parents, and autopsy materials from his deceased sister.
Given the unique constellation of signs and symptoms and the
familial nature, exome sequencing of both parents, both affected
siblings, and a third unaffected older female sibling was per-
formed as previously described.33 Exome sequencing was per-
formed on exon targets captured using the Agilent SureSelect
Human All Exon V4 (50 Mb) kit. After automated filtering of var-
iants with a minor allele frequency (MAF) of >10%, manual cu-
ration was performed to filter less common variants with MAF of
1%–10% and variants in genes inherited from unaffected par-
ents, evaluating predicted effects of rare variants and known
function of the genes and associated human conditions, and
examining overlapping phenotypes of individuals with de novo
variants in the same gene as previously described.33 In addition
to allele frequency, pathogenicity prediction algorithms, such
as PolyPhen2,34 SIFT,35 CADD,36 REVEL,37 and MetaSVM,38
were used for prioritizing variants.
Genomic DNA from participants 3, 4, and 5 and their parents
was isolated from whole blood using the chemagic DNA Blood
Kit special (PerkinElmer) or the QIAmp DNA Mini Kit (QIAGEN),
according to the manufacturer’s protocol. Exome sequencing
was performed as previously described.39 Exonic regions were en-
riched using the SureSelect Human All Exon kit (50Mb_v5) from
Agilent followed by sequencing as 100 bp paired-end runs on an
Illumina HiSeq2500. Exome sequencing for participants 3 and 4
and their parents was performed by Personalis (Personalis). Reads
were aligned to the human reference genome (UCSC Genome
Browser build hg19) using Burrows-Wheeler Aligner (v.0.7.5a).
Identification of single-nucleotide variants and small insertions
and deletions (indels) was performed with SAMtools (v.0.1.19).
For analysis of rare bi-allelic variants, only variants with a minor
allele frequency (MAF) of less than 1% in our internal database
of 14,000 exomes were considered.Tissue Immunohistochemistry, Cell Preparation, and
Culture
Tissue preparation, immunostaining, and semiquantitative evalua-
tion were done as described.40 Lymphoblastoid cell lines were
maintained after EBV immortalization. Fibroblasts were cultured
from a 3 mm punch skin biopsy. In addition to these cells, we
also purchased a control immortalized PBMC (ATCC #CRL5959)
of a normal individual (a 58-year-old male, European descent)
and two control primary fibroblasts (Coriell #GM07753 and
#GM07492) of apparently healthy individuals (both are 17-year-
oldmales, Europeandescent, namedCTL-17Maand -17Mb, respec-
tively). All the immortalized PBMCs were maintained in Iscove’s
Modified Dulbecco’s Medium (IMDM) supplemented with 15%
fetal bovine serum (FBS) and 4 mM L-Glutamine (Thermo Scienti-
fic). For prevention against bacteria, fungi, and mycoplasma, the
media also contained Penn Strep (Thermo Scientific), Normocin
(Invivogen), Nystatin suspension, and Amphotericin B solution
(Sigma Aldrich) according to manufacturers’ instructions. The pri-
mary fibroblasts were maintained in Dulbecco’s Modified Eagle’s
medium (DMEM) containing high glucose and GlutaMAX
(Thermo Scientific) and supplemented with 15% FBS and 1%
Penn Strep. Cells were incubated at 37C in a humidifiedCO2 incu-
bator. The immortalized PBMCs of less than 30 passages and pri-
mary fibroblasts of less than 20 passages were employed in the
experiments.erican Journal of Human Genetics 103, 100–114, July 5, 2018 101
Modeling of the Human FARS-tRNAphe Complex
Structure
The structure of the Thermus thermophilus tRNAPhe molecule (PDB:
2IY5) was docked into the crystal structure of human FARS (PDB:
3L4G) using the PathDock server41 and manually adjusted as pre-
viously described.42 All the structural figures were prepared with
Pymol.
RNA Isolation and Quantitative Real-Time PCR
Cultured cells were washed with 13 PBS twice before RNA extrac-
tion. Total RNA was extracted using RNAeasy Mini kit (Life
Technologies) with on-column TURBO DNase digestion (Life
Technologies). Isolated total RNA was quantified by NanoDrop
1000 spectrometer. For gene expression assessment by quantita-
tive real-time PCR, messenger RNA was captured by oligo(dT)18
primer and reverse-transcribed into cDNA using SuperScript III
Reverse-Transcriptase (Life Technologies). To minimize variation,
2 mg of total RNA was input in each reverse transcription reaction.
The cDNA then was purified using DNA purification kit (Omega)
and eluted in 400 mL of sterile water. The quantitative real-time
PCR was performed as described previously.14 The expression of
target genes was normalized to that of the housekeeping genes
RPL9 and RPL11 in each sample.
Western Blotting and Relative Band Intensity Analysis
Frozen aliquots of cells were lysed by the radioimmunoprecipi-
tation assay (RIPA) buffer (Bio-Rad) added with complete
protease inhibitors (Roche) at 4C for 15 min. The crude lysates
were further sonicated and followed with centrifugation at
12,000 3 g for 15 min at 4C. The supernatant containing total
cell extracts was quantified for protein concentration by the
Pierce BCA Protein Assay (Thermo Scientific). The western blot
was performed using primary antibodies (a-FARSb: Abnova
#H00010056-M01; a-FARSa: Abcam #54653) and the HRP-
conjugated secondary antibody. Protein bands were visualized
by chemiluminescence on the ChemiDoc Imaging System
(Bio-Rad). The relative band intensity was quantified by the
Image Lab software (Bio-Rad) according to manufacturer’s
instructions.
Aminoacylation Assay
Whole-cell extracts of immortalized PBMCs were prepared by lysis
with M-PER Mammalian Protein Extraction Reagent (Thermo
Scientific) in the presence of Halt Protease Inhibitor (Thermo
Scientific). Crude lysates were centrifuged at 14,000 3 g for
10 min at 4C. The supernatant containing total cell extracts
was transferred to clean eppendorf tubes. Protein concentrations
were measured using the Quick Start Bradford Protein Assay (Bio-
Rad). An equal amount of protein (7.5 mg per reaction) from each
sample was added to reaction mix containing 12.5 mg/mL yeast
tRNA (Sigma-Aldrich), 300 mM L-Phe or L-Gly, 1.6 mM [3H]-Phe
(American Radiolabeled Chemicals) or 6 mM [3H]-Gly (Perkin
Elmer), 4 mM ATP, 10 mM MgCl2, 2 mM DTT, 20 mM KCl, and
50 mM HEPES (pH 7.5). The reaction was stopped by addition
of quench solution consisting of 0.5 mg/mL DNA, 100 mM
EDTA, and 300mMNaOAc (pH 3.0). [3H]-Phe- or [3H]-Gly-labeled
tRNA was precipitated by addition of 20% TCA and captured us-
ing Multiscreen HTS filter plates (EMD Millipore). Filters were
washed with a 5% TCA, 100 mM Phe solution and captured
tRNA was solubilized with 0.1 M NaOH. Amount of [3H] was
quantified by addition of Optiphase Supermix scintillation102 The American Journal of Human Genetics 103, 100–114, July 5, 2cocktail (Perkin Elmer) and counting by a MicroBeta scintillation
counter (Perkin Elmer).Puromycin Incorporation Assay
Puromycin is a structural analog of tyrosyl-tRNA and can incor-
porate into nascent polypeptide chains during protein transla-
tion. Its incorporation in cultured cells followed with detection
using anti-puromycin antibodies has been developed as a
well-validated method to reflect the rate of global protein syn-
thesis.43,44 The cells were seeded 1 day before treatment and
incubated overnight. The seeding density was 6K cells/96-well
for immortalized PBMCs and 30K cells per 24-well for primary fi-
broblasts. The next day, after media refresh, cells were pulsed
with or without puromycin for 10 min. For cycloheximide
(CHX) inhibition of protein synthesis, cells were pre-treated
with 400 mg/mL CHX (Sigma) for 30 min. Media were
refreshed after the puromycin 5 CHX treatment and cells
were incubated in clean media for 1 hr in the CO2 incubator.
Then, cells were washed and detached with Accutase cell
detachment solution (Thermo Scientific) and transferred to the
96-well V-bottom plate for staining. The immortalized
PBMCs from 4 3 96-wells were combined and fibroblasts
from 1 3 24-wells were directly transferred to 1 staining well.
After PBS wash and spin down at 300 3 g for 5 min, cells
were first stained with 100 mL live/dead Zombie NIR (Biolegend)
at 1:1,000 dilution for 15 min at room temperature. After
PBS wash, the cells were resuspended in 60 mL Cytofix/
Cytoperm solution (BD Biosciences) and incubated on ice for
20 min. Cells were washed twice with Perm/Wash buffer (BD
Biosciences) and incubated with a-puromycin (DHSB #PMY-
2A4) for 45 min on ice in the dark. After washing, cells were
incubated with a-mouse IgG NL493 (R&D Systems) for 45 min,
and finally resuspended in FACS buffer (13 PBS supplemented
with 2% FBS) and kept at 4C until flow cytometry analysis by
the FACSARIA III system (BD Biosciences). The median fluores-
cence intensity (MFI) for each puromycin dose minus that of
the blank (puromycin ¼ 0) was employed for curve fitting by
Prism (Graphpad) using the log(agonist) versus response  vari-
able slope nonlinear regression to calculate EC50 of the puromy-
cin incorporation.Cell Proliferation Assay
Cell growth was determined using CellTiter-Glo Luminescent
Cell Viability Assay reagent (Promega) following manufacturer’s
instructions. Fibroblast cells were plated on 96-well plates at
1,000 cells per well and cultured in complete medium. Prolifer-
ation was measured every 24 hr for 120 hr and therefore at six
time points in total. Cells were lysed using freshly prepared
assay reagent and incubated for 10 min at each end point.
Cell lysates were then transferred to white flat-bottom plate
for luminescence measurement on a FLOUstar Optima plate
reader (BMG labtech). Cell growth was calculated relative to
time 0 for each cell.Statistical Analysis
Results of at least three biological replicates were represented as
mean 5 standard error of the mean (SEM). The significance of
difference between two groups was analyzed by Student’s t test,
and among multiple groups was analyzed by the one-way analysis
of variance (ANOVA) followed with Newman-Keuls’ multiple018
Table 1. Clinical Features of the Five Participants
Participant Family Gender Status
FARSB Genotype
(NM_005687.4)
Minor Allele
Frequency
(gnomAD)
CADD
Score36 Lung Histopathology Brain MRI Findings
1 1 M 18 yo c.848þ1G>A
(p.Arg305Gln)
.001%, .0008% 28.9, 35 pulmonary blebs, severe
emphysematous changes,
fibrosis, and cholesterol
accumulation
symmetric calcifications
of the subcortical white
matter in the cerebellum
and cerebrum
2 1 F deceased
(10 yo)
c.848þ1G>A
(p.Arg305Gln)
.001%, .0008% 28.9, 35 bilateral pulmonary
fibrosis with severe
chronic interstitial
pneumonitis and
cholesterol crystals
diffuse calcifications
and encephalomalacia
3 2 M deceased
(8 yo)
p.Arg401Gln,
p.Thr461Pro
not present,
not present
34, 31 interstitial lung disease
with fibrosis, alveolar
and interstitial accumulation
of cholesterol granulomas,
cysts, pulmonary alveolar
proteinosis
leukoencephalopathy
with symmetric
calcifications in basal
ganglia and cerebellum,
hydrocephalus e vacuo
4 3 F 10 yo p.Phe252Ser,
p.Arg401Gln
not present,
not present
29.9, 34 interstitial lung disease with
cholesterol pneumonitis,
non-specific interstitial
pneumonitis, desquamative
interstitial lung disease,
bronchial wall thickening,
cysts, formation of giant cells
phagocytosing hemosiderin,
cholesterol crystals
not assessed
5 4 F deceased
(8 yo 8 m)
p.Cys76Arg,
p.Lys262Glu
not present,
not present
27.2, 27.1 severe interstitial pneumonitis,
lymphocyte and plasma cell
infiltrate, cholesterol clefts,
multinucleate giant cells,
fibrosis and cysts
no significant abnormality
at 4 monthscomparison tests. The p values of less than 0.05were regarded as sta-
tistically different.Results
Clinical Characteristics of Participants
The clinical features of the five individuals are summarized
in Table 1. We evaluated a family with two similarly
affected children with recurrent pneumothoraces, intersti-
tial lung disease, hypertension, intracranial aneurysms and
calcifications, and cirrhosis of unclear etiology. Participant
1 (P1, Figures 1A–1D) is the second child born to unaf-
fected, non-consanguineous parents (father of Irish/
English descent and mother of Filipino descent). The
pregnancy was uncomplicated, and birth parameters
were within normal limits. He had a history of congenital
hypothyroidism. The proband presented at 6 months of
age with failure to thrive requiring gastrostomy tube
placement. Further neurologic workup revealed diffuse hy-
potonia and decreased muscle mass, with a muscle biopsyThe Amshowing hypereosinophilia of myocytes with diminished
type 1 muscle fibers and normal mitochondrial oxidative
phosphorylation. He subsequently had delayed motor
milestones, first walking at age 3, without any evidence
of intellectual disability. He had a spontaneous pneumo-
thorax at the age of 13 and imaging and histological
evaluation of the lungs demonstrated pulmonary blebs, se-
vere emphysematous changes, fibrosis, and cholesterol
granuloma consistent with prior injury (Figures 1K–1N).
He had evidence of restrictive lung disease and decreased
lung volumes on pulmonary function testing. He devel-
oped hypertension at the age of 14, and angiography
identified stenosis of the distal right renal artery. Patholog-
ical examination of the renal artery showedmarked disrup-
tion of the internal elastic lamina and fibrosis consistent
with fibromuscular dysplasia. Vascular imaging demon-
strated extensive intracerebral aneurysms within the
anterior and posterior circulation and fusiform dilatations
of the right carotid artery and basilar artery (Figure 1O).
Brain MRI showed symmetric calcifications of the
subcortical white matter in the cerebellum and cerebrumerican Journal of Human Genetics 103, 100–114, July 5, 2018 103
Brain Angiography
Connective
Tissue Findings Liver Kidney Hypertension
Muscle
Hypotonia
Intestinal
Malrotation
Dysmorphic
Features
extensive intracerebral
aneurysms within the
anterior and posterior
circulation, and fusiform
dilatations of the right
carotid artery and basilar
artery
scoliosis, pectus
excavatum, poor wound
healing, arachnodactyly,
positive wrist and
thumb signs, joint
hyperextensibility,
low bone mineral
density, and abdominal
hernia
cirrhosis renal artery
stenosis
with renal
artery stenosis
þ none micrognathia,
tooth crowding
extensive intracranial
aneurysms
scoliosis cirrhosis none untreated but
likely responsible
for brain aneurysm
hemorrhage
þ þ none
not assessed pectus excavatum, low
bone mineral density,
hyperextensibility of
joints
not assessed,
chronically
elevated
liver enzymes
mild
incomplete
tubular
proteinuria
þ þ frontal bossing,
deep and
narrow-set eyes
not assessed none increased
liver size,
elevated
liver enzymes
first 4 y of
life, later
normal
severe
bilateral
vesico-urethral
reflux (grade
3-4), treated
by operation
þ none prominent
forehead,
narrow-set
eyes
not assessed none moderate
steatosis
focal
segmental
glomerulo-
sclerosis
pulmonary
hypertension
þ none prominent
forehead, full
cheeks, small
nose, narrow
deep-set eyes,
myopathic facies,
unusual fat
distribution
over buttocks(Figure 1O). Notably, all echocardiograms including aortic
dimensions were normal. As an adolescent, he developed
scoliosis and pectus excavatum. He has a history of low
bone mineral density and poor wound healing. Upon
last evaluation at the age of 18 years, he was 170 cm tall
and 51.2 kg (BMI 17.7 kg/m2) with a physical examination
notable for features that overlap with Marfan syndrome
including micrognathia, tooth crowding, arachnodactyly,
positive wrist and thumb signs, joint hyperextensibility,
scoliosis, pectus excavatum, and abdominal hernia (Fig-
ures 1B–1D). He has no evidence of cognitive deficits and
attends college.
The proband’s younger sister (P2, Figures 1A and 1E) had
similar clinical features including difficulty gaining
weight, hypotonia, early gross motor delays, marfanoid
body habitus, scoliosis, recurrent pneumothoraces,
cirrhosis, intracranial aneurysms, stroke, hypertension,
and seizures. She died at 10 years of age due to an intracra-
nial hemorrhage caused by a ruptured aneurysm. Her au-
topsy showed bilateral pulmonary fibrosis with severe
chronic interstitial pneumonitis and cholesterol crystals.104 The American Journal of Human Genetics 103, 100–114, July 5, 2She had hepatomegaly with early cirrhosis, malrotation
of the intestines, and skeletal muscle myofiber enlarge-
ment and hypereosinophilia. Within the heart there were
scattered hypereosinophilic myocytes. Her brain was
microcephalic with diffuse calcification in the cerebellum
and cerebrum, encephalomalacia, and multiple saccular
aneurysms (Figures 1F–1J).
Participant 3 (P3, Figures 1A and 1P–1R) was the second
child born to unaffected, non-consanguineous parents of
European descent. The pregnancy, birth, and neonatal
period were uncomplicated. At the age of 3 months, he
had recurrent vomiting, was noted to be hypotonic, and
was incidentally found to have intestinal malrotation. A
brainMRI at 1 year of age showed demyelination of the nu-
cleus lentiformis and corona radiata. Muscle biopsy
demonstrated structurally normal but hypotrophic skeletal
muscle with increased fat accumulation and biochemical
analysis was suspicious of a partially impaired cyto-
chrome-c-oxidase (complex IV) activity. The individual
had low bone mineral density, mild tubular proteinuria,
frontal bossing, and deep-set eyes and had psychomotor018
Figure 1. Segregation of FARSB Mutations in the Family and Clinical Findings in the Subjects
(A) Pedigree with FARSB genotypes listed below each family member.
(B–D) Images of proband P1 highlighting pectus excavatum, poor wound healing, and arachnodactyly.
(E) Image of proband P2.
(F–J) Clinical findings in the proband P2. Low (F)- and high (G)-power views of the cortex. Low (H)- and high (I)-power views of the cere-
bellum.Mineral deposits, consistentwith calcifications (G–I).Hemosiderin-ladenmacrophages in cortex (J), consistentwithpriorbleeding.
(K–O) Clinical findings in the proband P1. Histopathology of lung revealing emphysema, sub-pleural fibrosis, and cholesterol
granuloma.
(K) Lung tissue shows diffuse alveolar simplification with dilated alveolar spaces.
(L) Emphysema is present with alveolar duct dilatation and mild interstitial thickening around dilated airspaces.
(M) Areas of severe bullous emphysema with characteristic floating ‘‘broken’’ septa are observed.
(N) Patches of macrophage accumulation and cholesterol clefts are observed, indicative of prior tissue injury. These areas also had dystro-
phic calcification (not shown).
(O) Brain imaging showing multiple large aneurysms and cerebral calcifications. (Top left) Magnetic resonance angiogram of the brain
without contrast showing the anterior circulationwith approximately 3mm right internal carotid artery cavernous aneurysm and a large
fusiform dilatation of the left carotid terminus extending into the left anterior carotid artery and left middle carotid artery. (Top right)
Similar aneurysms present in posterior circulation including a large, irregular fusiform aneurysm involving the basilar tip, right superior
cerebral artery, and right posterior cerebral artery, and to lesser extent left posterior cerebral artery. (Bottom left) MRI brain without
contrast, susceptibility weighted imaging signal with low signal throughout the bilateral subcortical white matter within the cerebellar
and cerebral hemispheres. These findings again likely represent calcifications. (Bottom right) T1 shortening embolism within the bilat-
eral deep gray nuclei likely representing calcifications, less likely hemorrhage.
(P–R) Images of proband P3 were taken at age 0.5 (P), 5 (Q), and 6 (R) years. Note frontal bossing, deep and narrow-set eyes (P, Q), and
pads on dorsal proximal phalanges (R).
(S–U) Clinical findings in P3. Chest imaging showed interstitial lung disease with diffuse ground glass attenuation and subpleural and
paraseptal cystic lesions (S). Lung histology with intraalveolar and interstitial cholesterol granuloma with giant cells and cholesterol
crystals, round cell infiltrate, foamy macrophages, cuboid metaplasia of alveolar type II cells, subpleural emphysematous spaces,
increased intraalveolar accumulation of surfactant (T, HE-stain), also demonstrated by strong staining with antibodies against SP-A
(U), summarized as focal cholesterol pneumonitis and pulmonary alveolar proteinosis.
(V–Z) Images of proband P4 were taken at age 4 months (V), age 16 months (W), and age 10 years (Z). Note prominent forehead and
narrow-set eyes (V, W). Initial CT with bilateral interstitial consolidations and ground-glass opacity in the upper lobes, more on the
left than right, and bilateral pleural effusion. A year later, previously affected areas are cystic, as well as subpleural cystic lesions, inter-
lobular septal thickening, and ground-glass attenuation (X, Y).
(AA and AB) Images of proband 5 were taken at 4 years old and demonstrate prominent forehead, full cheeks, deep-set eyes, myopathic
facies (AA), and unusual fat distribution (AB).
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delay and speech delay before entering school (Figures 1P–
1R). An MRI at the age of 6 years showed dilation of the
lateral ventricles and leukoencephalopathywith symmetric
calcifications in the basal ganglia and cerebellum. He was
laterhospitalizedwith clubbing, pectus excavatum, inspira-
tory wheezing, tachydyspnea, and retractions. Chest imag-
ing demonstrated bilateral diffuse ground glass, increased
reticular interstitial markings, and cysts (Figure 1S). Histo-
logic evaluation of the lungs demonstrated alveolar and
interstitial accumulation of huge cholesterol granulomas
with foreign-body giant cells, consistent with cholesterol
pneumonia in combination with extensive areas of pulmo-
nary alveolar proteinosis (Figure 1T), as demonstrated by
alveolar fillingwith surfactant protein (SP) A-positivemate-
rial (Figure 1U). Additional staining demonstrated the
presence of SP-B, pro-SP-B, but not pro-SP-C and SP-D,
and alveolar macrophages and T lymphocytes (Figures
S1A–S1C). Due to respiratory failure, he received a lung
transplant at the age of 8. The explanted lungs were grossly
yellowand stiff, confirming severe cholesterol pneumonitis
and fibrosis. The post transplantation course was compli-
cated with chronic effusion and infections, and he died
10 months later due to transplant rejection.
Participant 4 (P4, Figures 1A, 1V, 1W, and 1Z) is the
second child of four children born to healthy, non-consan-
guineous parents of European ancestry. Distinct facial fea-
tures included a prominent forehead and narrow-set eyes
(Figures 1V and 1W). At the age of 3 months, she presented
with failure to thrive and vomiting and was found to be
hypotonic. At 5 months of age, diffuse lung infiltrates
were noted, developing to bronchial wall thickening and
lung fibrosis on chest CT (Figures 1X and 1Y). Pads on dor-
sal phalanges and digital clubbing were observed. Histopa-
thology revealed a combination of non-specific interstitial
pneumonitis and desquamative interstitial pneumonitis
with intra-alveolar cholesterol granuloma. The latter were
surrounded by alveolar macrophages and T lymphocytes
(Figures S1D–S1F). At age 10 years she has normal psycho-
motor development.
Participant 5 (P5, Figures 1A, 1AA, and 1AB) was the first
child born to non-consanguineous parents. Their second
child died from the consequences of extreme prematurity
after delivery at 24 weeks gestation. Both parents had
healthy children from prior partners. Participant 5 was a
vaginal breech delivery at termwith normal growth param-
eters but gainedweight poorlywith significant gastresopha-
geal reflux. At 3 months of age, she was evaluated for
marked hypotonia, and nerve conduction studies and a
brain MRI showed no significant abnormality. She demon-
strated gross motor delays, sitting at 10 months. At 2 years
of age she was microcephalic with occipital frontal circum-
ference below first percentile. She had distinctive facial fea-
tures including deep-set eyes, a small nose, and full cheeks.
Amuscle biopsy was performed and showed normal histol-
ogy with respiratory chain biochemistry consistent with a
complex 1 deficiency, with normal results for complexes
II–IV. She had continued difficulty gaining weight due to106 The American Journal of Human Genetics 103, 100–114, July 5, 2chronic vomiting and diarrhea, which were improved
with pancreatic supplements. She was also found to have
low serum albumin, hypertriglyceridemia, and proteinuria,
leading to a renal biopsy showing features of focal
segmental glomerulosclerosis. At age 2, she was also noted
to have mild hepatosplenomegaly, with later liver biopsy
showing chronic inflammation and macrovesicular steato-
sis. She gradually developed tachypnea and oxygen depen-
dency by 3 years old. Pulmonary imaging and biopsy
showed features of interstitial pneumonitis, which were
believed to be secondary to aspiration, leading to fundopli-
cation surgery. These measures improved feeding manage-
ment and she was relatively stable at age 4, demonstrating
normal speech and language and cognitive development.
Byage6herpulmonary statusdeclined, and shewasoxygen
dependent 24 hr per day. Lung biopsy at age 8 revealed
distortion of alveolar architecture, foreign body-associated
giant cell reaction,numerous cholesterol clefts, andchronic
inflammatory cell infiltrates. By 8 she required mechanical
ventilation. She developed pulmonary hypertension and
died suddenly at home of a cardiac arrest at 8 years.
No mutations in known disease genes explaining the
phenotype were identified in any of the five affected partic-
ipants. Exome sequencing in all five affected participants
identified bi-allelic rare, predicted pathogenic variants in
FARSB (GenBank: NM_005687.4) that were all confirmed
by Sanger sequencing (Figure 1A). All missense variants
occurred at highly conserved residues and were predicted
to be pathogenic by multiple prediction algorithms, and
CADD scores are shown in Table 1. All variants were either
absent or present with aminor allele frequency of less than
1 in 1,000 in gnomAD. Participants 1 and 2 had paternally
inherited canonical splice site variant, c.848þ1G>A, and
a maternally inherited missense variant c.914G>A
(p.Arg305Gln), present at a highly conserved residue
(Figure 1A). Participant 3 had a paternally inherited
c.1202G>A (p.Arg401Gln) and a maternally inherited
c.1381A>C (p.Thr461Pro) variant identified; participant
4 had a maternally inherited c.1202G>A (p.Arg401Gln)
variant shared with P3 and a paternally inherited
c.755T>C (p.Phe252Ser) identified; and participant 5 had
c.784A>G (p.Lys262Glu) and c.226T>C (p.Cys76Arg) var-
iants (Figure 1A).
In summary, all five individuals presented with common
features of hypotonia and interstitial lung disease with
cholesterol pneumonitis, all with bi-allelic variants in
FARSB. Additional variable features were multisystemic
and included the vasculature (extensive cerebral aneu-
rysms, hypertension), brain (cerebral calcifications), liver
(cirrhosis and transaminitis), intestines (malrotation), kid-
neys (proteinuria), connective tissue (scoliosis and pectus
excavatum), and distinctive facial features.
Prediction of Structural Impact of FARSB Missense
Mutations
The six disease-associated missense mutations of FARSB
are highly conserved and located in various domains018
Figure 2. The Missense Mutations Are
Located in Various Domains of FARSb
(A) The schematic of FARSb protein and
location of the missense mutations in
various domains.
(B) Location of the mutational sites on the
structural model of the human FARS-
tRNAPhe complex. The protein and tRNA
backbones are shown in cartoon represen-
tation. Two FARS a chains are colored in
dark and light blue, two b-chains in dark
and light magenta, and tRNAPhe in orange.
The amino acids at the mutational sites are
shown in sticks and colored in red. Based
on the model, residues Lys262 and
Arg305 are closer to tRNAPhe (<10 A˚), while
the other four residues (Cys76, Phe252,
Arg401, and Thr461) have a longer dis-
tance (>15 A˚) from tRNAPhe. None of these
residues are directly involved in the inter-
action with tRNA.including B1, B3_4, B5, and B-core (Figures 2A). The B3_4
domain is the editing domain of FARS. The B5 domain in
the bacteria FARS was suggested to bind DNA.45,46 The
B-core domain dimerizes with the FARS a chain aminoacy-
lation domain. The eukaryotic B1 domain is shorter than
the bacterial counterpart, and its function is unclear.
None of the mutated residues are known to be directly
involved in aminoacylation, editing, or tRNA binding. To
predict the impact of these mutations on FARS structure
and function, we docked tRNAPhe into the crystal structure
of human FARS as described previously.42 We found that,
in the FARS-tRNAPhe model (Figure 2B), Lys262 has a
distance of 6.5 A˚ to the 30 end CCA tail of tRNA. In addi-
tion to the change of the residue charge from positive to
negative, the p.Lys262Glu mutation is predicted to abolish
the hydrogen bonding with Gln267 in the alpha chain
(Figure 3C). This may lead to a change of local structure
and affect loading of the amino acid to the tRNA CCA-
end. The other residues have a longer distance from
tRNAPhe (8 A˚ for Arg305 and >15 A˚ for Cys76, Phe252,
Arg401, and Thr461). In terms of the structural impact of
the mutations, Thr461 is located in an alpha-helix, and
its substitution by the helix breaker proline is expected
to disrupt the helical structure, which possibly affects the
overall protein structure (Figure 3F). The p.Cys76Arg
mutation is predicted to create a new hydrogen bond
with Met273 in the adjacent alpha-helix (Figure 3A).
The residue charge changes from neutral to positive, and
the extended side chain of arginine may introduce
structural hindrance to affect the local structure.The American Journal of Humap.Arg305Gln and p.Arg401Gln are
predicted to abolish some hydrogen
bonding with spatially adjacent resi-
dues, and the change from positive
to neutral charge may also eliminate
electrostatic interactions (Figures 3D
and 3E). These may affect the stabilityof local structures, but themutational impact on the global
structure and translational function of FARS is uncertain.
Phe252 is located in the same b strand encompassing
Glu254 and Thr256, the proposed key editing site on
human FARS.42 p.Phe252Ser is predicted not to affect
hydrogen bonding with adjacent residues, but this muta-
tion removes the phenyl ring and changes the residue
from hydrophobic to hydrophilic (Figure 3B). Whether
this change affects the local structure and editing activity
of FARS remains to be elucidated.
The FARSB c.848þ1G>A Mutation Alters Splicing and
Acts as a Null Allele
The c.848þ1G>A substitution of P1 and P2 alters a canon-
ical splice site47 and is predicted to result in skipping of
exon 9 and then to cause a frameshift (Figure 4A). We per-
formed PCR on cDNA prepared frommRNA extracted from
whole blood and used primers flanking exons 7 and 10 to
analyze transcripts that should include exon 9. As ex-
pected, the FARSB transcript with deletion of exon 9,
FARSB-DE9, was detected in the proband who carries the
c.848þ1G>Amutation (Figure 4B). In contrast, themother
who does not carry this splice mutation expressed only the
full-length transcript. Disruption of canonical splicing of
intron 9 reduced the amount of full-length transcript in
the proband compared to the mother. Next, using quanti-
tative real-time PCR, we quantified the expression of FARSB
in primary fibroblasts from the proband, both parents, and
three normal control subjects (Table S1). Consistent with
the above PCR results, FARSB-DE9 expression was detectedn Genetics 103, 100–114, July 5, 2018 107
Figure 3. Predicted Impact of Missense Muta-
tions on FARS Structure
Pairwise comparisons between the wild-type and
mutant residues for changes in local contacts
with other amino acids. The highlighted residues
are shown in sticks and labeled. The hydrogen
bonds are presented as yellow dash lines.
(A) Cys76 forms hydrogen-bonding with adja-
cent residues Gly79 and Leu80. The p.Cys76Arg
mutation appears not to affect these hydrogen
bonds but creates a new hydrogen bond with
Met273 in the adjacent a-helix.
(B) Phe252 forms hydrogen bonds with
His162, which appear to be unaffected by the
p.Phe252Ser mutation.
(C) Lys262 is 6.5 A˚ from the tRNA CCA-end. It
forms hydrogen bonds with adjacent residues
Asp259, Ile265, and Val266 located in the
same b-chain and Gln267 in the a chain. The
p.Lys262Glu mutation is predicted to abolish
the hydrogen bonding with a-Gln267.
(D) Arg305 forms hydrogen bonds with residues
Ile351 and Ile358 in the b-chain and Gln308 in
the a-chain. The p.Arg305Gln mutation is pre-
dicted to disrupt the hydrogen bonding with
b-Ile358 and a-Gln308. Arg305 has a distance of
8 A˚ to the tRNAPhe and no direct contact.
(E) Arg401 may form hydrogen bonds with
Glu397, Glu398, Met404, Ala405, and Glu411
in the b-chain and Ser232 in the a-chain. The
p.Arg401Gln mutation is predicted to disrupt
the hydrogen bonding with a-Ser232.
(F) Thr461 is located in an a-helical structure and
forms hydrogen bonds with Gly457, Leu458,
Ala464, and Asn465. p.Thr461Pro disrupts the
hydrogen bonding with Gly457 and Leu458,
and proline is known to be a helix-breaker, thus
the p.Thr461Pro mutation is expected to disrupt
the helical structure.only in the proband and the father who both carry the
c.848þ1G>A mutation, and not in the mother or in the
three control subjects (Figure 4C). Relative to the mother108 The American Journal of Human Genetics 103, 100–114, July 5, 2018and controls, there was a reduction of
more than 50% of the full-length FARSB
transcript for the proband and father (to
27.5% and 35.2% of control, respectively).
Exon 9 is located in the middle of the
FARSB transcript and encodes the end of
the B3-4 domain and partial linker to the
B5 domain (Figure S2A). Failure to include
exon 9 with 62 nucleotides changes the
reading frame and is predicted to introduce
a premature termination codon in exon 10
(after joining of exons 8 and 10) and is
predicted to activate nonsense-mediated
mRNA decay.48 Indeed, western blots using
an N-terminal FARSb antibody targeting the
region of amino acids 161–248 showed no
protein product of the DE9 variant in the
primary fibroblasts or immortalized periph-
eral blood mononuclear cells (PBMCs)
(Figure S2B and Table S1). These results areconsistent with the expected consequences of the canoni-
cal splice c.848þ1G>A substitution in FARSB and suggest
that this allele acts as a loss of function.
Figure 4. The c848þ1G>A Intronic
Mutation Resulted in Aberrant Splicing
of FARSB
(A) The mutation of the universal splice
site motif is expected to affect the splicing
of nearby exons in the FARSB gene, such as
skipping of the adjacent exon 9.
(B) A splice variant that deleted exon 9 of
the FARSB_FL transcript, designated as
FARSB-DE9, was detected in the proband
but not in the mother.
(C) Quantitative real-time PCR analysis of
mRNA expressions of FARSB_E9-11 (using
primers targeting exons 9 and 11 of FARSB,
thus primarily detecting the full-length
transcript), and FARSB-DE9 (using primers
specifically amplifying the DE9 variant) in
primary fibroblasts. Gene expression of
FARSB_E9-11 and -DE9 in the fibroblasts
of the proband, both parents, and three
control subjects were calculated based on
Ct values normalized to house-keeping
genes RPL9 and RPS11. The fold changes
were thus calculated by relative to the
FARSB_E9-11 level of CTL-17M. Data were
presented as mean 5 SEM. The DE9 RNA
was detected only in the proband and
father cells but not in the mother and con-
trol subjects (U.D. denotes no detectable
amplification within 45 qPCR cycles).We found no differences in transcript levels of FARSA in
fibroblasts among the six cell lines (affected individual,
parents, or three normal control subjects) (Figure 5A).
Comparing Transcript and Protein Levels of FARS a- and
b-Subunits
To further characterize the impact of the recessive muta-
tions, we compared transcripts and protein levels of FARSB
in fibroblasts from the proband, parents, and three age-
matched unrelated control subjects (Figure 5). FARS a-sub-
unit (FARSa) and cytoplasmic glycyl-tRNA synthetase
(GARS) were evaluated in parallel and, in all six cases,
expression of GARS transcripts and protein were identical.
Similar expression of a-subunit transcripts was observed
for all six subjects, but the amount of a-subunit protein
was substantially reduced for the proband and father.
Because the proband and father clearly had decreased
amounts of b-chain protein (FARSb), the results suggest
that the b-chain was needed to stabilize the a-chain.
Similar results were observed in immortalized PBMCs
(Figure S2C). The compound heterozygous mutations
were associated with 80% reduction of protein levels of
both the FARSb and FARSa.
Protein Synthesis Is Not Impaired in Proband Cells
For aminoacylation analysis, we used whole-cell extracts
from immortalized PBMCs normalized for total protein
content. We measured charging of Phe to yeast tRNA for
one normal control subject, the father, mother, andThe Amproband. Aminoacylation rates of the father and mother
were 67%–75% of the control subject, while the proband
was 37% of the control subject (Figure S3A). This apparent
reduction in aminoacylation rates was correlated with and
accounted for by a reduction of FARS protein levels in the
proband, father, and mother relative to the control (19%,
36%, and 55% of the control, respectively; Figure S2C).
Both the GARS (an internal control) protein levels and
rates of GARS aminoacylation for all four samples were
similar (Figure S3B). Thus, the p.Arg305Gln mutation has
little effect on charging activity in immortalized PBMCs
and, based on other work,19,49 suggests that decreased
levels of FARS activity in the proband are unlikely to affect
protein synthesis. To further evaluate this observation, we
used a puromycin incorporation assay to investigate pro-
tein synthesis. We found that the affected individual’s
PBMCs had similar rates of protein synthesis as those
from a control subject and father (Figures S3C–S3E).
We measured rates of protein synthesis in primary
fibroblasts from the proband, parents, and three
normal subjects, using the puromycin incorporation assay
(Figure 6A). A dot plot of the results from 3–4 independent
replicates of each of the 6 independently sourced fibro-
blasts showed no significant difference in rates of protein
synthesis (p > 0.15; Figure 6B). Thus, with these primary
cells we also did not observe a significant loss of the capac-
ity for protein synthesis.
To confirm that protein synthesis was sufficient to
support cell growth, primary fibroblast cell proliferationerican Journal of Human Genetics 103, 100–114, July 5, 2018 109
Figure 5. Compound Heterozygous
FARSB Mutations Reduced FARS Protein
Level in Proband Fibroblasts
(A) Gene expression of FARSA, FARSB, and
GARS in primary fibroblasts from proband,
parents, and control subjects by qPCR
analysis relative to house-keeping genes
RPL9 and RPS11 (n ¼ 3).
(B) Representative western blot results (bot-
tom panel) and calculated relative protein
levels (upper panel, n¼ 4) of FARSa, FARSb,
and GARS in primary fibroblasts. RPL11
was employed as the loading control.
Data were presented as mean 5 SEM.
Significant difference compared to the
respective age- and sex-matched control
is indicated by asterisks and labeled
directly above the sample bars, and that
between any two cells of the proband fam-
ily is indicated by asterisks above the lines
(*p < 0.05, **p < 0.01, and ***p < 0.001
by one-way ANOVA followed with New-
man-Keuls’ multiple comparisons).rates were measured. Interestingly, primary cell prolifera-
tion was significantly more rapid in the proband compared
to three control subjects (p< 0.001) (Figure 6C). These data
further support the conclusion that any reduced level of
FARS is not affecting the capacity for protein synthesis in
the affected individual.Discussion
We describe a novel genetic disorder with an unusual
multi-organ phenotype of interstitial lung disease with
cholesterol pneumonitis, intracranial aneurysms, cerebral
calcifications, hypotonia, and liver cirrhosis caused by bi-
allelic mutations in FARSB. Other less consistent features
include renal disease, intestinal malrotation, and dysmor-
phic facial features. The most consistent and life-limiting
feature so far has been pulmonary disease although partic-
ipants were not systematically investigated for all the
features observed across all individuals, and were evaluated
at different ages. The associated mutations include a
c.848þ1G>A splice mutation that leads to exon skipping
and a frameshift in the transcript, and decreased transcript
and protein levels of FARSB, which collectively suggest that
this is a loss-of-function allele. Both FARSb and FARSa pro-
tein levels were diminished, demonstrating the deleterious
effects of these mutations on FARSb protein levels and, as a
consequence, the destabilization of FARSa. The missense
p.Arg305Gln allele is associated with slightly reduced
aminoacylation rates that correlated with the reduced
amount of FARS protein. Yet, the proband had normal rates110 The American Journal of Human Genetics 103, 100–114, July 5, 2018of protein synthesis and increased
cellular proliferation in the investi-
gated cells. We also identified three
additional, unrelated individuals
with overlapping phenotypes, eachwith compound heterozygous missense mutations in
FARSB. The lack of any phenotype in carrier parents and
carrier siblings suggest that only the individuals with the
compound heterozygous mutations have fallen below a
critical threshold for a secondary function of FARSB
beyond that of protein translation. Recently, another
family with an affected child with bi-allelic, FARSB variants
(p.Thr256Met and p.His496Lysfs*14) that includes one
predicted loss-of-function allele and a missense variant
with very similar clinical features was identified,50 support-
ing our conclusions.
In previous efforts to investigate the impact of aaRS
genetic mutations on the canonical enzymatic function,
the in vitro aminoacylation assays were commonly
employed to study enzyme kinetics.16 Some studies
also measured the amount of charged tRNA in partici-
pants’ cells or analyzed the mutated genes in yeast
complementation assays.23–25,30,51 However, it is unclear
how well the changes observed in these assays correlate
with a significant compromise of cellular translation.
The puromycin incorporation assay used here is an
effective way to evaluate overall protein synthesis in
cultured cells, to test whether a mutation affects
the cellular translational machinery and, if not, to point
to a disease mechanism due to an orthogonal, non-
canonical function of aaRS. Consistently, we demon-
strated that the proband’s cells harboring the bi-allelic
FARSB mutations showed no decline of overall protein
synthesis.
There are a total of 37 human aaRSs (17 cytoplasmic,
17 mitochondrial, and 3 bifunctional), each of which is
Figure 6. Protein SynthesisWas Not Impaired in the Proband Fi-
broblasts
(A) The global protein synthesis was evaluated by puromycin
incorporation in cultured fibroblasts of the proband, family, and
control subjects. Shown are mean 5 SEM of normalized median
fluorescence intensity (MFI) from 3–4 separate experiments (left
panel). The dose-response curves were fitted by log(agonist) versus
normalized response variable slope nonlinear regression (Prism).
(B) Dot-plot of the calculated EC50 of puromycin incorporation
(each independent test shown as a dot). No statistical signifi-
cance was found among the groups based on the one-way
ANOVA (p > 0.15).
(C) Cell proliferation of cultured fibroblasts of the proband, both
parents, and four control subjects. Data were presented as
mean5 SEM. Time courses revealed faster proliferation in the pro-
band fibroblast than others (***p < 0.001).specific for a single amino acid.16 These enzymes are highly
conserved and ubiquitously expressed across all tissues.
The aaRSs also have roles outside of protein synthesis,
some of which are independent of this catalytic activity
and include nuclear regulation of transcription, extracel-
lular receptor mediated signaling, and mTOR regula-
tion.14
Most aaRSs that have been implicated in human diseases
are associated with primary manifestations in the central
and peripheral nervous system. To date, 31 of the 37 aaRSs
have been linked to monogenic diseases.16 Given the
essential and non-redundant functions of these enzymes,
recessively inherited aaRS disorders are generally causedThe Amby compound heterozygous hypomorphic alleles rather
than by homozygous null alleles.16
Although the novel disease caused by FARSB mutations
described here shares some similarities with other known
aaRS disorders, it is unique in other ways. None of the
known aaRS diseases have extensive vascular and multi-
organ manifestations, involving the lungs, brain, liver,
kidney, intestine, and vasculature. However, other dis-
eases caused by mutations encoding both non-polar
and hydrophobic amino acid aaRSs share some clinical
aspects with our FARSB individuals. For instance, reces-
sive mutations in MARS (encoding methionyl-tRNA
synthetase) (MIM: 615486) are associated with hypoto-
nia, endocrine dysfunction, liver disease characterized
by lobular disarray, canalicular cholestasis, steatosis,
and iron deposition.25 Of interest, individuals with
MARSmutations share with all five participants described
here an extremely rare interstitial lung disease defined
by cholesterol pneumonitis.32,52 Autosomal-recessive
IARS (encoding isoleucyl-tRNA synthetase) (MIM:
617093) deficiency is associated with liver disease, hypo-
tonia, and intellectual disability.23,24 In contrast to our
findings with deficiency of cytoplasmic FARSB, com-
pound heterozygous mutations in nuclear-encoded
FARS2 (the mitochondrial phenylalanyl-tRNA synthe-
tase) lead to combined oxidative phosphorylation defi-
ciency associated with global developmental delay, re-
fractory seizures, and lactic acidosis.53 Interestingly, in
three individuals (P1, P3, and P5) a mitochondrial dis-
ease was suspected clinically. In P5, complex I activity
was decreased, an observation similar to individuals
with mutations in IARS.23 FARS, MARS, and IARS are
part of a multi-synthetase complex (MSC), which is orga-
nized by nine cytoplasmic aaRSs and three aaRS-interact-
ing multifunctional proteins AIMP1, AIMP2, and
AIMP3.2,3,54 Some aspects of the clinical phenotype
may be related to such non-canonical functions or to
involvement in the MSC.
Thus, despite the essential role of aaRSs in protein
translation in all cells, recessive mutations in aaRSs lead
to tissue-specific disease phenotypes that are likely due
to the specificity of the additional role of these transcripts
in other tissue-specific cellular functions beyond protein
translation. Our results define a new genetic syndrome
characterized by diffuse parenchymal (interstitial) lung
disease, hypertension, intracranial aneurysms, cerebral
calcifications, and liver cirrhosis due to compound het-
erozygous mutations in FARSB. These findings expand
our knowledge of the diverse roles of aaRSs in human
disease and further support the importance of the now
well-established expanded functions of the higher
eukaryote tRNA synthetases, some of which (e.g., DNA
binding45,46) may have their roots in bacterial ancestors.
Further functional assays of these FARSB variants in
modeling systems are in progress and will cast light on
the disease mechanism and the expanded functions of
FARS.erican Journal of Human Genetics 103, 100–114, July 5, 2018 111
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